Document Detail


An updated systematic review with meta-analysis for the clinical evidence of silymarin.
MedLine Citation:
PMID:  18334810     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The potential benefit of silymarin (special extract from the fruits of Silybum marianum) in the treatment of liver diseases remains a controversial issue. METHODS: For this systematic review electronic databases identified 65 papers for the search terms silymarin, silibinin, silicristin or milk thistle and clinical trial. Only 19 complied with the criteria'double-' or 'single-blind'. These publications were analysed from a clinical point of view and meta-analytic calculations were performed. RESULTS: The clinical evidence ofa therapeutic effect of silymarin in toxic liver diseases is scarce. There is no evidence of a favourable influence on the evolution of viral hepatitis, particularly hepatitis C. In alcoholic liver disease, comparing with placebo, aspartate aminotransferase was reduced in the silymarin-treated groups (p = 0.01) while alkaline phosphatase was not. In liver cirrhosis, mostly alcoholic, total mortality was 16.1% with silymarin vs. 20.5% with placebo (n.s.); liver-related mortality was 10.0% with silymarin vs. 17.3% with placebo(p = 0.01). CONCLUSIONS: Based on the available clinical evidence it can be concluded - concerning possible risks /probable benefits - that it is reasonable to employ silymarin as a supportive element in the therapy of Amanita phalloides poisoning but also (alcoholic and grade Child 'A') liver cirrhosis. A consistent research programme, consolidating existing evidence and exploring new potential uses,would be very welcome.
Authors:
Reinhard Saller; Reto Brignoli; Jörg Melzer; Rémy Meier
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Forschende Komplementärmedizin (2006)     Volume:  15     ISSN:  1661-4127     ISO Abbreviation:  -     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-03-12     Completed Date:  2008-08-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101269884     Medline TA:  Forsch Komplementmed     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  9-20     Citation Subset:  IM    
Affiliation:
Institute of Complementary Medicine, Department of Internal Medicine, University Hospital Zurich, Switzerland. reinhard.saller@usz.ch
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amanita
Clinical Trials as Topic
Hepatitis C / drug therapy
Humans
Iatrogenic Disease
Liver Diseases / drug therapy
Silymarin / pharmacokinetics,  therapeutic use*
Chemical
Reg. No./Substance:
0/Silymarin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hypophosphatasia associated with pseudotumor cerebri and respiratory insufficiency.
Next Document:  Adjuvant simultaneous mistletoe chemotherapy in breast cancer--influence on immunological parameters...